Today: 9 June 2026
Browse Category

NASDAQ:CBRL 9 December 2025 - 10 December 2025

Cracker Barrel (CBRL) Stock Tumbles After Q1 2026 Earnings Miss and Lowered Outlook: Latest News and Analyst Forecasts

Cracker Barrel (CBRL) Stock Tumbles After Q1 2026 Earnings Miss and Lowered Outlook: Latest News and Analyst Forecasts

Cracker Barrel shares fell as much as 8% pre-market December 10 after reporting a 5.7% drop in Q1 revenue to $797 million and a swing to a $25 million net loss. The company cut its full-year outlook, sending the stock to around $27, near its 52-week low and down over 60% from last year’s high. Major hedge fund Marshall Wace sharply increased its stake. Analyst targets were lowered, with sentiment remaining cautious.
10 December 2025
··
Top Pre‑Market Losers Today (December 10, 2025): AFJK, CBRL, DNLI & AEG Lead Early Declines Before the Bell

Top Pre‑Market Losers Today (December 10, 2025): AFJK, CBRL, DNLI & AEG Lead Early Declines Before the Bell

Aimei Health Technology plunged nearly 50% in pre-market trading after extending its business-combination deadline. Lion Group Holding and JX Luxventure Group each dropped over 35%. Broader U.S. stock futures showed little movement as investors awaited the Federal Reserve’s rate decision later today. Cracker Barrel and Denali Therapeutics also traded lower on fresh news and analyst calls.
10 December 2025
····
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 09.12.2025

The Dow fell 178 points while the S&P 500 slipped and the Nasdaq edged higher; the 10-year yield rose to 4.19%. October JOLTS openings reached 7.67 million, with hires down and the quits rate at a Covid-era low. Casey’s earnings beat forecasts; Cracker Barrel missed and cut guidance. Dow Inc. gained 1.09% despite a weak sector outlook.
9 December 2025
··

Stock Market Today

  • Toast (TOST) Stock Down 29% YTD Amid Mixed Valuation Signals
    June 9, 2026, 9:43 AM EDT. Toast (TOST) shares have fallen 29.2% year to date, hitting $24.10 after a 16.6% slide over three months. Market debate centers on whether the current price undervalues Toast's growth prospects or reflects headwinds in hospitality tech. A popular valuation narrative pegs fair value at $33.96, citing demand for Toast's AI-driven restaurant tools amid labor shortages and expansion into new markets. This represents a 29% discount to current trading levels. However, risks remain, including high sales costs and margin pressure from competition and tariffs. Investors weigh steady revenue growth and margin improvement against these challenges as Toast navigates a turbulent period.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Go toTop